Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2026)

Tango Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 48.82% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $30.0 million (up 1.83% YoY), while the FY2025 annual figure was $26.4 million, down 8.54% from the prior year.
• Share-based Compensation was $10.8 million for Q1 2026 at Tango Therapeutics, up from $6.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.8 million in Q1 2026 to a low of $3.2 million in Q1 2022.
• Historically, Share-based Compensation has averaged $5.8 million across 5 years, with a median of $6.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 237.37% in 2022, then slipped 19.86% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2022, then increased by 28.9% to $4.9 million in 2023, then jumped by 52.94% to $7.5 million in 2024, then retreated by 19.86% to $6.0 million in 2025, then surged by 80.55% to $10.8 million in 2026.
• The last three Share-based Compensation figures came in at $10.8 million (Q1 2026), $6.0 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.